WizTNA Injection

Adult administration

The dosage and infusion rate should be determined based on fat removal and dextrose metabolism capabilities, as well as the patient's condition, weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: Amino acids at 0.7–1.0 g/kg/day (0.10–0.15 g nitrogen/kg) - Patients under moderate to severe metabolic stress: Amino acids at 1.0–2.0 g/kg/day (0.15–0.30 g nitrogen/kg) should be administered as an infusion. Generally, amino acids should be administered via central venous infusion at a total of 0.7–1.3 g/kg/day (0.10–0.20 g nitrogen/kg), equivalent to 19–38 mL/kg of this medication daily.

This medication must be used under a doctor's direction. If serious allergic symptoms, such as anaphylactic reactions (fever, chills, rash, difficulty in breathing, etc.) occur, administration must be stopped immediately. When used with intravenous calcium-containing preparations, precipitation may occur; thus, the same infusion device should not be used simultaneously, and the infusion line should be thoroughly washed before and after administration. Particular caution is needed for premature infants or low-birth-weight infants due to their decreased fat metabolism ability, which may pose risks. Patients with allergies to egg, soybean protein, severe hyperlipidemia, liver dysfunction, blood coagulation disorders, renal failure, and other specific conditions should not receive this medication. It should not be used in newborns and infants under 2 years of age, as well as in patients with hypokalemia. Patients with renal failure, liver dysfunction, hypothyroidism, sepsis, or any other fatty metabolism disorders should be administered cautiously. During administration, adverse reactions such as increased body temperature, chills, nausea, vomiting, and transient increases in liver enzyme levels may occur. When administered through a peripheral vein, thrombophlebitis may occur, so caution is needed. In cases of overdose, fatty overload syndrome may occur, hence the dosage and infusion rate must be strictly controlled. During the initial intravenous administration, the patient's condition should be closely monitored; if there is an electrolyte imbalance, it must be corrected before administration. When infusing through a central vein, aseptic techniques must be strictly followed to prevent infections. Blood triglyceride levels should be measured 5-6 hours post-infusion to confirm the fat elimination capability. During long-term administration, adequate nutritional supplementation is necessary considering the increased excretion of trace elements. Infusion with blood may cause agglutination reactions; hence, they should not be administered together. Blood glucose, electrolytes, fluid balance, acid-base status, and liver enzyme levels should be regularly monitored during administration. Patients with renal failure must carefully manage their phosphate and potassium intake, and electrolyte supplementation should be adjusted based on the patient's condition. In poorly nourished patients, administration should begin slowly, and the solution and nutrients must be carefully adjusted. In pregnant or breastfeeding women, safety has not been established, therefore it should only be administered when the therapeutic benefits outweigh the risks. Elderly patients should be cautious with slow administration rates and dose reductions as they have decreased physiological functions. After administration, 5-6 hours should pass before testing because the fatty components that may influence some test results will disappear from the blood, thus the timing of tests must be adjusted. In cases of overdose, symptoms such as nausea, vomiting, sweating, fluid overload, electrolyte imbalance, and hyperglycemia may occur; if symptoms arise, the infusion rate should be slowed or stopped. This medication should not be used if the packaging is damaged or if the solution is cloudy or separated, and any remaining solution should be discarded after use.

Serious side effects

Anaphylactic reactions (including urticaria), skin rashes, difficulty in breathing, hyperventilation, fever, chills, severe rash with high fever, blisters, skin peeling, pain in oral/ocular mucosa, severe swelling, shortness of breath, chest tightness, clammy skin, pallor, swelling associated with elevated blood pressure, coma.

Mild side effects

Increased body temperature, chills, nausea/vomiting, transient increase in liver enzymes, thrombophlebitis during peripheral venous infusion, hypertension or hypotension, hemolysis, reticulocytosis, abdominal pain, headache, fatigue, penile erection, hyperlipidemia, fat deposition, liver enlargement, spleen enlargement, anemia, leukopenia, thrombocytopenia, blood coagulation disorders.

This medication should be stored in a sealed container to protect it from air and moisture, and it is recommended to keep it in a cool place at a temperature between 0 to 25 degrees. Storing it this way helps maintain the medication's effectiveness and prevents deterioration.

Appearance

This medication consists of an internal bag and external packaging made of plastic for infusion solution, divided into three compartments, with an oxygen absorber placed between them. Each internal compartment contains a dextrose solution, amino acids, and electrolytes.

Package unit

1026mL/bag, 1540mL/bag, 2053mL/bag